LIVIVO - Search results -

Search results

Result 1 - 10 of total 40

Search options

Article ; Online: Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia.

Minagawa, Hikaru / Hashii, Yoshiko / Nakajima, Hiroko / Fujiki, Fumihiro / Morimoto, Soyoko / Nakata, Jun / Shirakawa, Toshiro / Katayama, Takane / Tsuboi, Akihiro / Ozono, Keiichi

BMC cancer

2023 Volume 23, Issue 1, Page(s) 167

Abstract: Background: A Wilms' tumor 1 (WT1) oral vaccine, Bifidobacterium longum (B. longum) 420, in which the bacterium is used as a vector for WT1 protein, triggers immune responses through cellular immunity consisting of cytotoxic T lymphocytes (CTLs) and ... ...

Abstract	Background: A Wilms' tumor 1 (WT1) oral vaccine, Bifidobacterium longum (B. longum) 420, in which the bacterium is used as a vector for WT1 protein, triggers immune responses through cellular immunity consisting of cytotoxic T lymphocytes (CTLs) and other immunocompetent cells (e.g., helper T cells). We developed a novel, oral, helper epitope-containing WT1 protein vaccine (B. longum 2656) to examine whether or not B. longum 420/2656 combination further accelerates the CD4 Methods: C1498-murine WT1-a genetically-engineered, murine leukemia cell line to express murine WT1-was used as tumor cell. Female C57BL/6 J mice were allocated to the B. longum 420, 2656, and 420/2656 combination groups. The day of subcutaneous inoculation of tumor cells was considered as day 0, and successful engraftment was verified on day 7. The oral administration of the vaccine by gavage was initiated on day 8. Tumor volume, the frequency and phenotypes of WT1-specific CTLs in CD8 Results: Tumor volume was significantly smaller (p < 0.01) in the B. longum 420/2656 combination group than in the B. longum 420 group on day 24. WT1-specific CTL frequency in CD8 Conclusions: B. longum 420/2656 combination further accelerated antitumor activity that relies on WT1-specific CTLs in the tumor compared with B. longum 420.
MeSH term(s)	Female ; Animals ; Mice ; WT1 Proteins ; CD8-Positive T-Lymphocytes ; Epitopes ; Mice, Inbred C57BL ; T-Lymphocytes, Cytotoxic ; Wilms Tumor ; Interferon-gamma ; Cancer Vaccines ; Leukemia ; Kidney Neoplasms
Chemical Substances	WT1 Proteins ; Epitopes ; Interferon-gamma (82115-62-6) ; Cancer Vaccines ; WT1 protein, mouse
Language	English
Publishing date	2023-02-20
Publishing country	England
Document type	Journal Article
ZDB-ID	2041352-X
ISSN	1471-2407 ; 1471-2407
ISSN (online)	1471-2407
ISSN	1471-2407
DOI	10.1186/s12885-023-10547-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.

Fujiki, Fumihiro / Morimoto, Soyoko / Nishida, Yuya / Tanii, Satoe / Aoyama, Nao / Inatome, Miki / Inoue, Kento / Katsuhara, Akiko / Nakajima, Hiroko / Nakata, Jun / Nishida, Sumiyuki / Tsuboi, Akihiro / Oka, Yoshihiro / Oji, Yusuke / Sogo, Shinji / Sugiyama, Haruo

Cancer immunology, immunotherapy : CII

2023 Volume 72, Issue 7, Page(s) 2347–2356

Abstract: ... ...

Abstract	CD4
MeSH term(s)	Humans ; Immunotherapy, Adoptive/methods ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/metabolism ; CD4-Positive T-Lymphocytes ; Neoplasms ; Antigens, Neoplasm
Chemical Substances	Receptors, Antigen, T-Cell ; Antigens, Neoplasm
Language	English
Publishing date	2023-03-20
Publishing country	Germany
Document type	Journal Article
ZDB-ID	195342-4
ISSN	1432-0851 ; 0340-7004
ISSN (online)	1432-0851
ISSN	0340-7004
DOI	10.1007/s00262-023-03420-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1237: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia.

Nakagawa, Natsuki / Hashii, Yoshiko / Kayama, Hisako / Okumura, Ryu / Nakajima, Hiroko / Minagawa, Hikaru / Morimoto, Soyoko / Fujiki, Fumihiro / Nakata, Jun / Shirakawa, Toshiro / Katayama, Takane / Takeda, Kiyoshi / Tsuboi, Akihiro / Ozono, Keiichi

Cancer immunology, immunotherapy : CII

2022 Volume 72, Issue 1, Page(s) 39–53

Abstract: Wilms' tumor 1 (WT1) is a promising tumor-associated antigen for cancer immunotherapy. We developed an oral protein vaccine platform composed of WT1-anchored, genetically engineered Bifidobacterium longum (B. longum) and conducted an in vivo study in ... ...

Abstract	Wilms' tumor 1 (WT1) is a promising tumor-associated antigen for cancer immunotherapy. We developed an oral protein vaccine platform composed of WT1-anchored, genetically engineered Bifidobacterium longum (B. longum) and conducted an in vivo study in mice to examine its anticancer activity. Mice were orally treated with phosphate-buffered saline, wild-type B. longum105-A, B. longum 2012 displaying only galacto-N-biose/lacto-N-biose I-binding protein (GLBP), and WT1 protein- and GLBP-expressing B. longum 420. Tumor size reduced significantly in the B. longum 420 group than in the B. longum 105-A and 2012 groups (P < 0.00 l each), indicating B. longum 420's antitumor activity via WT1-specific immune responses. CD8
MeSH term(s)	Mice ; Animals ; WT1 Proteins ; Bifidobacterium longum ; CD8-Positive T-Lymphocytes ; Leukemia, Myeloid, Acute ; Cancer Vaccines
Chemical Substances	WT1 Proteins ; Cancer Vaccines ; WT1 protein, mouse
Language	English
Publishing date	2022-06-14
Publishing country	Germany
Document type	Journal Article
ZDB-ID	195342-4
ISSN	1432-0851 ; 0340-7004
ISSN (online)	1432-0851
ISSN	0340-7004
DOI	10.1007/s00262-022-03214-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1237: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.

Journal of immunotherapy (Hagerstown, Md. : 1997)

2023 Volume 45, Issue 1, Page(s) 56–66

Abstract: The HLA-A*24:02-restricted peptide vaccine targeting Wilms' tumor 1 (WT1) (WT1 vaccine) is a promising therapeutic strategy for ovarian cancer; however, its efficacy varies among patients. In this study, we analyzed WT1-specific immune responses in ... ...

Abstract	The HLA-A*24:02-restricted peptide vaccine targeting Wilms' tumor 1 (WT1) (WT1 vaccine) is a promising therapeutic strategy for ovarian cancer; however, its efficacy varies among patients. In this study, we analyzed WT1-specific immune responses in patients with advanced or recurrent ovarian cancer that was refractory to standard chemotherapies and their associations with clinical outcomes. In 25 patients, the WT1 vaccine was administered subcutaneously weekly for 3 months and biweekly thereafter until disease progression or severe adverse events. We assessed Wilms' tumor 1-specific cytotoxic T lymphocytes (WT1-CTLs) and Wilms' tumor 1 peptide-specific immunoglobulin G (WT1235-IgG). After vaccination, the percentage of tetramer high-avidity population of WT1-CTLs among CD8+ T lymphocytes (%tet-hi WT1-CTL) and the WT1235-IgG titer increased significantly, although the values were extremely low or below the limit of detection before vaccination (%tet-hi WT1-CTL: 0.003%-0.103%.; WT1235-IgG: <0.05-0.077 U/mL). Patients who had %tet-hi WT1-CTL of ≥0.25% (n=6) or WT1235-IgG of ≥0.10 U/mL (n=12) had a significantly longer progression-free survival than those of patients in the other groups. In addition, an increase in WT1235-IgG corresponded to a significantly longer progression-free survival (P=0.0496). In patients with systemic inflammation, as evidenced by elevated C-reactive protein levels, the induction of tet-hi WT1-CTL or WT1235-IgG was insufficient. Decreased serum albumin levels, multiple tumor lesions, poor performance status, and excess ascites negatively influenced the clinical effectiveness of the WT1 vaccine. In conclusion, the WT1 vaccine induced antigen-specific cellular and humoral immunity in patients with refractory ovarian cancer. Both %tet-hi WT1-CTL and WT1235-IgG levels are prognostic markers for the WT1 vaccine.
MeSH term(s)	Cancer Vaccines ; Humans ; Immunity, Humoral ; Kidney Neoplasms ; Neoplasm Recurrence, Local ; Ovarian Neoplasms/therapy ; Peptides ; T-Lymphocytes, Cytotoxic ; Vaccines, Subunit ; WT1 Proteins
Chemical Substances	Cancer Vaccines ; Peptides ; Vaccines, Subunit ; WT1 Proteins ; WT1 protein, human
Language	English
Publishing date	2023-09-01
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1064067-8
ISSN	1537-4513 ; 1053-8550 ; 1524-9557
ISSN (online)	1537-4513
ISSN	1053-8550 ; 1524-9557
DOI	10.1097/CJI.0000000000000405
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1778: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy.

Fujiki, Fumihiro / Morimoto, Soyoko / Katsuhara, Akiko / Okuda, Akane / Ogawa, Saeka / Ueda, Eriko / Miyazaki, Maki / Isotani, Ayako / Ikawa, Masahito / Nishida, Sumiyuki / Nakajima, Hiroko / Tsuboi, Akihiro / Oka, Yoshihiro / Nakata, Jun / Hosen, Naoki / Kumanogoh, Atsushi / Oji, Yusuke / Sugiyama, Haruo

Frontiers in immunology

2022 Volume 13, Page(s) 935465

Abstract: Memory T cells play an essential role in infectious and tumor immunity. Vitamin A metabolites such as retinoic acid are immune modulators, but the role of vitamin A metabolism in memory T-cell differentiation is unclear. In this study, we identified ... ...

Abstract	Memory T cells play an essential role in infectious and tumor immunity. Vitamin A metabolites such as retinoic acid are immune modulators, but the role of vitamin A metabolism in memory T-cell differentiation is unclear. In this study, we identified retinol dehydrogenase 10 (Rdh10), which metabolizes vitamin A to retinal (RAL), as a key molecule for regulating T cell differentiation. T cell-specific Rdh10 deficiency enhanced memory T-cell formation through blocking RAL production in infection model. Epigenetic profiling revealed that retinoic acid receptor (RAR) signaling activated by vitamin A metabolites induced comprehensive epigenetic repression of memory T cell-associated genes, including TCF7, thereby promoting effector T-cell differentiation. Importantly, memory T cells generated by Rdh deficiency and blocking RAR signaling elicited potent anti-tumor responses in adoptive T-cell transfer setting. Thus, T cell differentiation is regulated by vitamin A metabolism and its signaling, which should be novel targets for memory T cell-based cancer immunotherapy.
MeSH term(s)	Alcohol Oxidoreductases/genetics ; Alcohol Oxidoreductases/metabolism ; Immunotherapy ; Memory T Cells ; Neoplasms/therapy ; Tretinoin/pharmacology ; Vitamin A/metabolism
Chemical Substances	Vitamin A (11103-57-4) ; Tretinoin (5688UTC01R) ; Alcohol Oxidoreductases (EC 1.1.-)
Language	English
Publishing date	2022-06-30
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2022.935465
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.

Alzaaqi, Shouq / Naka, Norifumi / Hamada, Kenichiro / Hosen, Naoki / Kanegae, Mizuki / Outani, Hidetatsu / Adachi, Mayuko / Imanishi, Rin / Morii, Eiichi / Iwai, Miki / Nakata, Jun / Fujiki, Fumihiro / Morimoto, Soyoko / Nakajima, Hiroko / Nishida, Sumiyuki / Tsuboi, Akihiro / Oka, Yoshihiro / Sugiyama, Haruo / Oji, Yusuke

Oncology letters

2022 Volume 23, Issue 2, Page(s) 65

Abstract: The Wilms' tumor gene WT1 is highly expressed in various malignancies and may be a common target antigen for cancer immunotherapy. In our group, peptide-based cancer vaccines targeting WT1 CTL epitopes were developed as an immunotherapy for these ... ...

Abstract	The Wilms' tumor gene WT1 is highly expressed in various malignancies and may be a common target antigen for cancer immunotherapy. In our group, peptide-based cancer vaccines targeting WT1 CTL epitopes were developed as an immunotherapy for these malignancies. In the present study, WT1 epitope-specific immune responses were analyzed in 31 patients with advanced sarcoma with human leukocyte antigen-A*24:02- and WT1-expressing tumors who received the WT1-235 peptide vaccine as monotherapy. The serum levels of IgG and IgM antibodies against the target epitope WT1-235 and the non-target epitopes WT1-332 and WT1-271 were measured using ELISA. IgM antibodies against WT1-235, WT1-332 and WT1-271 were detected in three (9.6%), four (12.9%) and 20 patients (64.5%), respectively, prior to vaccine administration, indicating immune recognition of the WT1 antigen prior to administering the vaccine. Of 15 patients who had completed the 3-month treatment protocol, WT1-235 IgG was positive in five (33.3%) patients. An enzyme-linked immunospot assay revealed that WT1-235 epitope-specific IL-10 production/secretion in peripheral blood mononuclear cells declined in the first month of vaccine administration in all three patients with positivity for WT1-235 IgM at the start of the vaccine. Furthermore, positivity for both WT1-235 and WT1-271 IgM antibodies at the start of treatment was associated with unfavorable tumor control at 3 months after vaccine administration. These results suggested that WT1 epitope-specific IgG and IgM antibodies may be utilized as immune-monitoring markers for WT1 peptide cancer vaccine immunotherapy. The trials were entered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry (https://www.umin.ac.jp/ctr; no. UMIN000002001 on May 24, 2009 and no. UMIN000015997 on December 20, 2014).
Language	English
Publishing date	2022-01-03
Publishing country	Greece
Document type	Journal Article
ZDB-ID	2573196-8
ISSN	1792-1082 ; 1792-1074
ISSN (online)	1792-1082
ISSN	1792-1074
DOI	10.3892/ol.2022.13184
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Imaging Assessment of Tumor Response in the Era of Immunotherapy.

Nakata, Jun / Isohashi, Kayako / Oka, Yoshihiro / Nakajima, Hiroko / Morimoto, Soyoko / Fujiki, Fumihiro / Oji, Yusuke / Tsuboi, Akihiro / Kumanogoh, Atsushi / Hashimoto, Naoya / Hatazawa, Jun / Sugiyama, Haruo

Diagnostics (Basel, Switzerland)

2021 Volume 11, Issue 6

Abstract: Assessment of tumor response during treatment is one of the most important purposes of imaging. Before the appearance of immunotherapy, response evaluation criteria in solid tumors (RECIST) and positron emission tomography response criteria in solid ... ...

Abstract	Assessment of tumor response during treatment is one of the most important purposes of imaging. Before the appearance of immunotherapy, response evaluation criteria in solid tumors (RECIST) and positron emission tomography response criteria in solid tumors (PERCIST) were, respectively, the established morphologic and metabolic response criteria, and cessation of treatment was recommended when progressive disease was detected according to these criteria. However, various types of immunotherapy have been developed over the past 20 years, which show novel false positive findings on images, as well as distinct response patterns from conventional therapies. Antitumor immune response itself causes 18F-fluorodeoxyglucose (FDG) uptake in tumor sites, known as "flare phenomenon", so that positron emission tomography using FDG can no longer accurately identify remaining tumors. Furthermore, tumors often initially increase, followed by stability or decrease resulting from immunotherapy, which is called "pseudoprogression", so that progressive disease cannot be confirmed by computed tomography or magnetic resonance imaging at a single time point. As a result, neither RECIST nor PERCIST can accurately predict the response to immunotherapy, and therefore several new response criteria fixed for immunotherapy have been proposed. However, these criteria are still controversial, and also require months for response confirmation. The establishment of optimal response criteria and the development of new imaging technologies other than FDG are therefore urgently needed. In this review, we summarize the false positive images and the revision of response criteria for each immunotherapy, in order to avoid discontinuation of a truly effective immunotherapy.
Language	English
Publishing date	2021-06-05
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2662336-5
ISSN	2075-4418
ISSN	2075-4418
DOI	10.3390/diagnostics11061041
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Reader-free ELISPOT assay for immuno-monitoring in peptide-based cancer vaccine immunotherapy.

Hayashi, Sae / Imanishi, Rin / Adachi, Mayuko / Ikejima, Sayaka / Nakata, Jun / Morimoto, Soyoko / Fujiki, Fumihiro / Nishida, Sumiyuki / Tsuboi, Akihiro / Hosen, Naoki / Nakajima, Hiroko / Hasegawa, Kana / Oka, Yoshihiro / Sugiyama, Haruo / Oji, Yusuke

Biomedical reports

2020 Volume 12, Issue 5, Page(s) 244–250

Abstract: Cancer vaccine immunotherapy is a therapy that induces cellular immune responses against a target molecule to elicit clinical anti-tumor effects. These cellular immune responses against the target molecule are monitored to evaluate whether the antigen- ... ...

Abstract	Cancer vaccine immunotherapy is a therapy that induces cellular immune responses against a target molecule to elicit clinical anti-tumor effects. These cellular immune responses against the target molecule are monitored to evaluate whether the antigen-specific cellular immune responses are induced and maintained during the vaccination period. Enzyme-linked immunospot (ELISPOT) assay is widely performed to analyze not only the frequency of immune cells, but also their effector functions as determined by their cytokine production/secretion. The present study aimed to develop a reader-free ELISPOT assay using a handy membrane-punching device termed ELI 8. With the assistance of particle analysis by ImageJ software, the results of spot counting were reproducible with high inter-assay and inter-examiner concordance. Immune cells that produce and secrete Th1 cytokines without antigen-peptide stimulation of peripheral blood mononuclear cells (PBMCs) were detected, and their frequencies in patients with cancer were significantly higher compared with those in healthy individuals. These frequencies varied between individuals, as well as between time points during the course of cancer vaccine immunotherapy in each patient. Due to the variability in spontaneous cytokine production/secretion by PBMCs, an antigen-specific immune response (IR) index is proposed, which is a ratio of the number of spot-forming cells (SFCs) subjected to antigen-stimulation to that of SFCs with spontaneous cytokine secretion without antigen-stimulation. This index may be used as a marker for antigen-specific cellular immune responses in patients treated with cancer immunotherapy. The IR index successfully detected the induction of Wilms' tumor 1-specific cellular immune responses in patients with cancer treated with cancer vaccine immunotherapy.
Language	English
Publishing date	2020-03-05
Publishing country	England
Document type	Journal Article
ZDB-ID	2763624-0
ISSN	2049-9442 ; 2049-9434
ISSN (online)	2049-9442
ISSN	2049-9434
DOI	10.3892/br.2020.1289
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.

Fujiki, Fumihiro / Tsuboi, Akihiro / Morimoto, Soyoko / Hashimoto, Naoya / Inatome, Miki / Nakajima, Hiroko / Nakata, Jun / Nishida, Sumiyuki / Hasegawa, Kana / Hosen, Naoki / Oka, Yoshihiro / Oji, Yusuke / Sogo, Shinji / Sugiyama, Haruo

Cancer immunology, immunotherapy : CII

2020 Volume 70, Issue 1, Page(s) 253–263

Abstract: Simultaneous induction of tumor antigen-specific cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) is required for an optimal anti-tumor immune response. ... ...

Abstract	Simultaneous induction of tumor antigen-specific cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) is required for an optimal anti-tumor immune response. WT1
MeSH term(s)	Antigens, Neoplasm/immunology ; CD5 Antigens/immunology ; Cancer Vaccines/immunology ; Cell Death/immunology ; Cell Proliferation/physiology ; Cells, Cultured ; Humans ; Leukocytes, Mononuclear/immunology ; Neoplasm Recurrence, Local/immunology ; Peptides/immunology ; T-Lymphocytes, Cytotoxic/immunology ; T-Lymphocytes, Helper-Inducer/immunology ; Vaccination/methods ; Vaccines, Subunit/immunology ; WT1 Proteins/immunology
Chemical Substances	Antigens, Neoplasm ; CD5 Antigens ; Cancer Vaccines ; Peptides ; Vaccines, Subunit ; WT1 Proteins ; WT1 protein, human
Language	English
Publishing date	2020-07-22
Publishing country	Germany
Document type	Journal Article
ZDB-ID	195342-4
ISSN	1432-0851 ; 0340-7004
ISSN (online)	1432-0851
ISSN	0340-7004
DOI	10.1007/s00262-020-02675-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1237: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Identification of mouse helper epitopes for WT1-specific CD4

Nakajima, Hiroko / Nakata, Jun / Imafuku, Kanako / Hayashibara, Hiromu / Isokawa, Kazuki / Udaka, Keiko / Fujiki, Fumihiro / Morimoto, Soyoko / Hasegawa, Kana / Hosen, Naoki / Hashii, Yoshiko / Nishida, Sumiyuki / Tsuboi, Akihiro / Oka, Yoshihiro / Oji, Yusuke / Sogo, Shinji / Sugiyama, Haruo

Cancer immunology, immunotherapy : CII

2021 Volume 70, Issue 11, Page(s) 3323–3335

Abstract: Helper T lymphocytes (HTLs) play a central role in cancer immunity because they can not only help the induction and proliferation of cytotoxic T lymphocytes (CTLs) but also their differentiation into cytotoxic ... ...

Abstract	Helper T lymphocytes (HTLs) play a central role in cancer immunity because they can not only help the induction and proliferation of cytotoxic T lymphocytes (CTLs) but also their differentiation into cytotoxic CD4
MeSH term(s)	Animals ; Antigens, Neoplasm/immunology ; Epitopes, T-Lymphocyte/immunology ; Male ; Mice ; Mice, Inbred C57BL ; T-Lymphocytes, Cytotoxic/immunology ; T-Lymphocytes, Helper-Inducer/immunology ; WT1 Proteins/immunology
Chemical Substances	Antigens, Neoplasm ; Epitopes, T-Lymphocyte ; WT1 Proteins ; WT1 protein, mouse
Language	English
Publishing date	2021-07-16
Publishing country	Germany
Document type	Journal Article
ZDB-ID	195342-4
ISSN	1432-0851 ; 0340-7004
ISSN (online)	1432-0851
ISSN	0340-7004
DOI	10.1007/s00262-021-03003-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1237: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito